Mounjaro®
Starting from £179.99/mo
Start journey Learn moreFluoxetine and Mounjaro (tirzepatide) are not known to have a direct pharmacokinetic interaction, and many people take antidepressants alongside weight-loss treatment. That said, combining any prescription medicines requires a prescriber to review your full medication list before tirzepatide is approved — this is a clinical decision, not a box-tick. The sections below explain what to watch for, what to tell your prescriber, and why the check matters even when the combination looks straightforward on paper. Mounjaro is a prescription-only medicine for weight management, and every prescription requires individual clinical assessment.
At your door the next working day.
Free, tracked, plain packaging.
BMI isn't the whole story, but it's where clinicians start. Check yours in ten seconds — nothing is stored, nothing is shared.
Ten seconds. Private — nothing is stored or shared.
Your result updates live in the card alongside.
Your result
Your BMI is
—
which is in the healthy weight range
Start journeyBMI doesn't determine eligibility — only a clinician can assess whether treatment is right for you.
The problem
The nume way
clinician review. Free next working day delivery.
How it works
Tell us about your health, history and goals. Free, online, and confidential — no commitment, no waiting room.
Our team reviews your health the same day — never an algorithm, and approves your treatment there and then if eligible.
Order by 12pm, dispatched same day, delivered free the next working day — the nume Promise.
Based on current UK prescribing references, including the tirzepatide Summary of Product Characteristics published on the electronic Medicines Compendium, no direct clinically significant interaction between fluoxetine and tirzepatide has been identified. That is reassuring as a starting point. It does not, however, mean the combination is automatically appropriate for every individual.
What matters practically is the broader picture: how long you have been on fluoxetine, your current dose, how well it is managing your mood, and any other medicines you take alongside it. Tirzepatide is a dual GIP and GLP-1 receptor agonist that works partly by slowing gastric emptying. When the stomach empties more slowly, oral medicines can take longer to reach the small intestine where absorption happens. For fluoxetine (which is taken orally) this could, in theory, shift the timing of how it is absorbed. Real-world evidence for a meaningful clinical effect on fluoxetine specifically is limited, but it is one of the things a prescriber considers. The NHS patient information for tirzepatide advises people to tell their doctor or pharmacist about all medicines they are taking, for exactly this reason.
The short version: no red flag, but a conversation with a clinician is still necessary. Worth checking that your antidepressant dose has been stable for at least several weeks before starting any new treatment, that stability is useful information for your prescriber.
Fluoxetine is a selective serotonin reuptake inhibitor. In some people it has appetite-suppressing effects, and weight change (either loss or gain depending on the individual and duration of treatment) is a recognised part of its profile. Tirzepatide works in a fundamentally different way: it activates gut hormone receptors that signal fullness to the brain, reducing hunger and slowing digestion. The two appetite-related mechanisms are distinct.
Because mood and appetite are connected, a prescriber will want to be confident that your mental health is stable and well-managed before adding tirzepatide. Significant uncontrolled depression or anxiety can complicate adherence to a new treatment and can also influence the physical symptoms some people notice during dose increases (things like nausea, fatigue, or changes in energy) in ways that are harder to interpret if mood is already fluctuating.
This is not a reason to assume the combination is unsuitable. Many people taking antidepressants have been assessed and prescribed tirzepatide without issue. It is a reason to be open about your mental health during the consultation. If you are wondering more broadly about your eligibility for Mounjaro, the eligibility page covers the full picture of what prescribers assess.
Be specific. Rather than listing fluoxetine as a medicine you take, tell your prescriber the dose you are on and how long you have been taking it, and whether it was prescribed for depression, anxiety, OCD, or another indication. Also mention any other medicines or supplements in your routine. Some supplements interact with SSRIs, and a few interact with GLP-1 medicines too, and if you are wondering whether something like creatine fits into that picture, the page on taking creatine alongside Mounjaro is a good example of how those supplement-specific questions get worked through. If you are curious about a specific supplement, the page on NMN and Mounjaro is one example of how those questions get answered.
If your GP prescribed your fluoxetine, it is worth making sure they know you are starting tirzepatide. At nume, we notify your GP when we prescribe, which keeps everyone in the loop. That is not just a courtesy, it means your GP can flag anything relevant in your medical history that did not come up in the consultation, and it means your care stays joined up.
One practical habit: before your consultation, open your medicine cabinet and check the name and dose of every product you take regularly, including over-the-counter medicines, vitamins and supplements. Writing them down takes under a minute and makes the consultation significantly more thorough. Our prescribers ask about this during every assessment, it is easier when you have the list in front of you.
Being prescribed an antidepressant does not automatically disqualify anyone from tirzepatide treatment. The licensed eligibility criteria for Mounjaro relate to BMI and weight-related health conditions: a BMI of 30 or above, or 27 or above alongside at least one condition such as hypertension, type 2 diabetes, dyslipidaemia, or obstructive sleep apnoea. The BMI eligibility guide explains these thresholds in detail.
What the prescriber is assessing is not just whether you meet the numbers but whether starting tirzepatide now is the right clinical decision for you specifically. Mental health status is one factor in that assessment, not because antidepressant users are excluded, but because prescribers take a whole-person view. If your depression or anxiety is actively unstable, a prescriber might suggest stabilising that first. If it is well-managed, as it is for many people on long-term fluoxetine, that is useful information that supports a straightforward assessment.
Our clinical team reviews consultations the same day they are submitted. If you want to understand how our process works, the about us page covers our clinical infrastructure, including our prescriber oversight. Questions about other health conditions and Mounjaro come up regularly, the page on Mounjaro and chronic kidney disease is one example of how condition-specific queries are handled. For a full view of available weight-loss treatments, the weight-loss treatments overview is a good place to start.
If you are ready to discuss your situation with a prescriber, you can speak to our prescribers through a free consultation, your full medication list, including fluoxetine, is part of what they review before anything is prescribed.
The people
Superintendent Pharmacist (GPhC No. 2217101)
Accountable for the safe running of our registered pharmacy, from every dispensing check to every dispatch.
Clinical Lead (GPhC No. 2231744)
Sets our clinical standards and checks everything we publish against current MHRA guidance.
Independent Prescriber (GPhC No. 2084501)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.
Independent Prescriber (GPhC No. 2083426)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.